Mentus Life Science

Mentus Life Science is a clinical-stage biotechnology company focused on developing novel treatments for central nervous system (CNS) disorders and chronic pain management. The company specializes in the reformulation and optimized delivery of established therapeutic agents to improve safety profiles, reduce side effects, and enhance clinical outcomes. Its lead program, MLS-101, is a proprietary small molecule formulation targeting the NMDA receptor for the treatment of various pain conditions. Mentus aims to provide effective non-opioid alternatives to address the global opioid crisis and improve the quality of life for patients with debilitating neurological conditions. The company leverages its expertise in drug delivery and CNS pharmacology to advance a pipeline of candidates through clinical development.